Clinical trials: Advanced Solid Tumors Patients
Neoplasms
A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors
This study will determine the maximum tolerated dose and the optimal associated 4 weekly dosing schedule of RO5045337, administered as monotherapy in patients with advanced solid tumors.
- Trial name
- NCT00559533
- Testing
- RO5045337
- Where
- 7 sites in United States, France
- Volunteers
- 106 people
- Sponsor
- Hoffmann-La Roche
Advanced Tumor
Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of PM1032 for patients with advanced tumors, also to explore the recommended Phase Ⅱ Dose（RP2D） of PM1032.
- Trial name
- NCT05839106
- Testing
- PM1032 injection
- Where
- 3 sites in China
- Volunteers
- 200 people
- Sponsor
- Biotheus Inc.
Neoplasms
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
This study will evaluate the safety and tolerability of R1507 in combination with 12 distinct standard chemotherapy drug regimens and an additional R1507 monotherapy arm in patients with advanced malignant neoplasms.The 12…
- Trial name
- NCT00811993
- Testing
- RG1507, RO1507, bevacizumab [Avastin]
- Where
- 8 sites in United States
- Volunteers
- 104 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
- Trial name
- NCT06715124
- Testing
- QTX3544, Cetuximab
- Where
- 10 sites in United States
- Volunteers
- 237 people
- Sponsor
- Quanta Therapeutics
Solid Tumors, Adult
Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors
A phase 1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, antigen-specific immune response and preliminary antitumor activity associated with VB10.NEO administered in combination…
- Trial name
- NCT05018273
- Testing
- VB10.NEO
- Where
- 12 sites in United States, Germany and 1 more
- Volunteers
- 26 people
- Sponsor
- Nykode Therapeutics ASA
Metastatic or Locally Advanced Solid Tumors
A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors
This is a phase 1, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of Y101D in patients with metastatic or locally advanced solid tumors.
- Trial name
- NCT05028556
- Testing
- Cohort 1 of Y101D, Cohort 2 of Y101D, Cohort 3 of Y101D
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Advanced Malignant Tumors
A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors
This is a Phase 1/2, open-label, dose escalation and dose expansion study designed to characterize the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of IBB0979 in previously treated patients with…
- Trial name
- NCT05991583
- Testing
- IBB0979
- Where
- China
- Volunteers
- 25 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Solid Tumor, Non-small Cell Lung Cancer
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT07623369
- Testing
- HH160
- Where
- 3 sites in Australia, China
- Volunteers
- 299 people
- Sponsor
- Huahui Health
Advanced Solid Tumors
A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available
The purpose of this study is to determine if IMC-A12 is safe for patients, and also to determine the best dose of IMC-A12 to give to patients.
- Trial name
- NCT00785941
- Testing
- IMC-A12
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Eli Lilly and Company
Cancer
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
This open-label, Phase Ib study that has six treatment arms is designed to assess the safety, pharmacology and preliminary efficacy of atezolizumab (MPDL3280A; an engineered anti-programmed death-ligand 1 [PDL1] antibody)…
- Trial name
- NCT01633970
- Testing
- 5-FU, Atezolizumab, Bevacizumab
- Where
- 11 sites in United States
- Volunteers
- 240 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumour
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.
- Trial name
- NCT07390383
- Testing
- LBL-024 for Injection, Capecitabine tablets, Tislelizumab Injection
- Where
- 7 sites in China
- Volunteers
- 110 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Advanced Solid Tumor
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
AFM24-102 is a Phase 1/2a open-label, non-randomized, multicenter, dose escalation, and expansion study evaluating AFM24 in combination with atezolizumab in patients with selected EGRF-expressing advanced solid malignancies whose…
- Trial name
- NCT05109442
- Testing
- AFM24, Atezolizumab 840 MG in 14 ML Injection
- Where
- 16 sites in United States, Poland and 3 more
- Volunteers
- 112 people
- Sponsor
- Affimed GmbH
Advanced Solid Tumors
An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors
This is an open, multi-center, dose-escalation/dose-expansion/efficacy expansion phase I clinical study to evaluate the tolerability, safety, PK, and immunogenicity of SHR-1826 in patients with advanced malignant solid tumors…
- Trial name
- NCT06094556
- Testing
- SHR-1826
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Solid Tumors, Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter
A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma
This is a multi-center, open label, non-randomized Phase 1 study, to be conducted in two parts, Part A, and Part B. Part A in solid tumors included the dose escalation phase for evaluating the safety and tolerability profile of…
- Trial name
- NCT02608125
- Testing
- PRN1371
- Where
- 12 sites in United States, Spain
- Volunteers
- 45 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Solid Tumor, Adult
A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors
This is a phase I, multicenter, open-label study. The study will investigate the safety, tolerability, PK, and preliminary efficacy of TY-2699a on locally advanced or metastatic solid tumors.
- Trial name
- NCT05866692
- Testing
- TY-2699a
- Where
- 2 sites in China
- Volunteers
- 156 people
- Sponsor
- TYK Medicines, Inc
Cancer, Solid Tumors
Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD7762 when given with the approved drug gemcitabine based on the side effects experienced by patients that…
- Conditions
- Cancer, Solid Tumors, Advanced Solid Malignancies
- Trial name
- NCT00937664
- Testing
- AZD7762, gemcitabine
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Malignant Neoplasms
Phase I Clinical Trial of YKYY031 for Injection in Patients With Advanced Solid Tumors
Phase I study of YKYY031 for injection in patients with advanced solid tumors
- Trial name
- YKYY031，tumors (NCT07631793)
- Testing
- YKYY031 group (the first stage), YKYY031 group (the second stage)
- Where
- 2 sites in China
- Volunteers
- 76 people
- Sponsor
- Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
Solid Tumor, Adult
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in participants with tumors.
- Trial name
- NCT03905148
- Testing
- Lifirafenib, mirdametinib
- Where
- 6 sites in United States, Australia
- Volunteers
- 91 people
- Sponsor
- BeiGene
Solid Tumor With p53 Wild Type Status
A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors
This is a first in human phase I study of single agent CGM097 in patients with advanced solid tumors who have progressed despite standard therapy or for whom no standard therapy exists.
- Trial name
- CCGM097X2101 (NCT01760525)
- Testing
- CGM097
- Where
- 5 sites in United States, France and 3 more
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
- Trial name
- NCT04449874
- Testing
- GDC-6036, Atezolizumab, Cetuximab
- Where
- 63 sites in United States, Australia and 15 more
- Volunteers
- 498 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.